Abbott has received a boost after shaking hands with AstraZeneca to promote the London-based company’s cholesterol-lowering drug Crestor (rosuvastatin calcium) in the US.

Through the agreement, Chicago-based Abbott has gained the non-exclusive right to promote Crestor alongside AstraZeneca in the US, excluding Puerto Rico. Financial terms of the agreement were not disclosed.

"This agreement will allow AstraZeneca to increase share of voice for Crestor among physicians whose patients may benefit from this therapy. We see this as a good fit for both companies as this agreement allows us to leverage Abbott's established presence in the dyslipidemia space," AstraZeneca vice president of primary care Mike Tilton said.

The deal follows a collaboration between the two companies in 2006 where they were aiming to develop a new cholesterol-busting pill. The plan was to develop a fixed-dose combination of AstraZeneca’s Crestor and Abbott’s investigational TriLipix (fenofibric acid) and submit a New Drug Application (NDA) to the FDA in 2009.

An NDA for TriLipix is currently being reviewed by the FDA for use as a monotherapy and in combinations with statins.

As part of the deal, the companies also looked at a combination of Crestor and Abbott’s next generation fenofibrate, ABT-335.

The combo pills aimed to target the three blood lipids that play a role in heart disease – the bad cholesterol LDL-C, the good cholesterol HDL-C and triglycerides.

According to AstraZeneca’s second quarter financial report, Crestor revenues increased 27% to $916 million.

In November last year, the drug was approved for treatment of atherosclerosis.